Pricing Log in Create free account
Friday 6 November 2026 Export XWEL’s income statement to Excel — free account

XWELL, Inc.

XWEL Healthcare Diagnostics & Research

XWELL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.2 million, down 13.8% from fiscal 2024.

Revenue
−7.08%
EPS
+53.6%
Free cash flow
−43.0%

Quarter to June 2026, against a year earlier

0.56 0.01 −1.75%
Market cap
$6.1M
P/E
0.0×
Fwd P/E
−4.4×
Dividend yield
—
F-score
3/9
Altman Z
−63.81
Beneish M
−6.38
Dividend safety
0/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 35.43%

Capital & Financial Ratios $m

Size
Market Cap 6.08
Revenue ttm 28.28
Net income ttm (22.36)
Free cash flow ttm (13.48)
Net debt Q (11.78)
Valuation
P/E 0.00
Forward P/E (4.35) (negative: loss-making)
Price / sales 0.17
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.59
Financial health
Current ratio Q 2.27 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (115.13)
Growth
Revenue growth Q −7.08% (below 0%: shrinking)
Operating income growth Q +21.84% (above 0%: growing)
EPS, this year +15.86% (at or above 15%: strong)
EPS, next year A +55.35% (at or above 15%: strong)
Revenue, next year A +29.61% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +20.00% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.1×, against a ten-year median of 0.2×; over the ten years it ranged from −3.4× in 2020 to 10.0× in 2021.
P/S against its own 10 years 22.00%
10-year low 10-year high
P/B against its own 10 years 43.53%
10-year low 10-year high
EV/FCF against its own 10 years 8.26%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 23 12 3 12
Receivables 2 2 2 2
Inventory 1 1 1 0
Other 1 1 1 1
27 15 6 15
2023 2024 2025 Q'26
Payables 1 2 3 2
ST’ Debt — — 4 —
Other — — — —
9 9 13 7

Compound Annual Growth %

10y 5y 3y
Sales 2.56% 28.35% (19.47%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY23 Estimate −0.80 Actual −0.76

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY22 −1.40 −1.60 Miss by 0.20
Q1 FY23 −2.60 −1.40 Beat by 1.20
Q2 FY23 −1.40 −1.40 Met by 0.00
Q3 FY23 −0.80 −0.76 Beat by 0.04

EPS $

Mar Jun Sep Dec Year
’26 (1.51) (0.26) — — —
’25 (1.00) (0.56) (0.26) (3.29) (5.08)
’24 (0.60) (0.48) (0.99) (1.55) (3.66)
’23 (1.40) (1.40) (2.76) (1.18) (6.64)
’22 (0.80) (1.60) (1.60) (3.00) (7.00)
’21 (0.20) (0.80) 1.00 0.60 0.60
’20 (34.80) (30.20) (2.00) 25.04 (41.00)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 7 7 — — —
’25 7 8 7 7 29
’24 9 9 8 7 34
’23 7 8 7 7 30
’22 24 14 11 8 56
’21 9 9 27 29 74
’20 8 0 0 0 8
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (5) — — —
’25 (4) (2) (2) 0 (9)
’24 (4) 0 (3) (3) (11)
’23 (6) (3) (4) (3) (16)
’22 (2) (7) (9) (7) (24)
’21 (3) 2 8 9 15
’20 (4) (8) (5) (8) (25)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (5) — — —
’25 (5) (3) (3) (1) (12)
’24 (4) (1) (4) (4) (13)
’23 (7) (3) (5) (3) (18)
’22 (4) (9) (11) (8) (31)
’21 (4) 0 6 6 7
’20 (4) (9) (7) (9) (29)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 12 49 50 49 8 74 56 30 34 29 28 +10.4% — — — —
Gross margin, % 43.78 20.15 21.25 21.97 (42.91) 43.87 21.54 12.23 26.31 25.70 34.34 (18.1) pt
EBT (19) (16) (36) (21) (92) 3 (33) (28) (16) (16) (22) (2.0%)
EBT margin, % (160.85) (32.77) (71.68) (42.62) (1,099.88) 4.00 (58.23) (92.98) (48.50) (55.04) (78.90) +105.8 pt
Net income (24) (28) (37) (21) (92) 3 (33) (28) (16) (16) (22) (4.3%)
Per share, $
Per share, $ Revenue 951.27 2,624.89 2,070.00 593.82 3.76 14.14 11.95 7.21 7.35 5.25 3.33 (43.9%)
Earnings (1,896.19) (1,548.15) (1,536.15) (259.80) (41.00) 0.60 (7.00) (6.64) (3.66) (5.08) (5.32) (48.2%)
Cash flow (669.92) (654.41) (271.32) (1.38) (11.22) 2.79 (5.17) (3.85) (2.39) (1.57) (1.33) (49.0%)
Capex (5.24) (245.27) (118.43) (27.85) (1.95) (1.46) (1.46) (0.57) (0.39) (0.53) (0.26) (22.4%)
Free cash flow (675.16) (899.68) (389.75) (29.23) (13.18) 1.34 (6.62) (4.42) (2.78) (2.10) (1.59) (47.3%)
Book value 5,092.78 2,464.46 542.77 (31.04) 36.07 19.16 10.24 5.02 1.68 (2.30) 0.97 n/m
Shares, m 0 0 0 0 2 5 5 4 5 6 7 +96.7%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 67.33 0.00 0.00 0.00 0.00 0.00 6.7
P/S 2.76 0.66 0.09 0.07 6.33 2.86 0.65 0.23 0.21 0.09 0.17 1.4
P/B 0.52 0.71 0.35 0.00 0.66 2.11 0.76 0.33 0.90 0.00 0.59 0.6
EV/Sales 1.81 0.67 0.29 0.22 (3.38) 1.53 (0.03) (0.40) (0.02) 0.18 (0.06) 0.1
EV/FCF (2.55) (1.94) (1.54) (4.39) 0.96 16.23 0.05 0.66 0.06 (0.44) 0.13 0.7
Cash, $m
Cash, $m Operating cash flow (8) (12) (7) 0 (25) 15 (24) (16) (11) (9) (11) +0.4%
Capex 0 (5) (3) (2) (4) (8) (7) (2) (2) (3) (2) +52.6%
Free cash flow (9) (17) (9) (2) (29) 7 (31) (18) (13) (12) (13) +3.6%
Balance, $m
Balance, $m Working capital 19 4 (11) (12) 78 89 36 17 6 (7) 8 n/m
Net debt (11) 0 3 7 (81) (99) (40) (23) (12) 1 (12) n/m
Shareholders’ equity 64 46 13 (3) 80 100 48 21 8 (13) 8 n/m
Returns, %
Returns, % ROA (36.03) (38.96) (77.65) (71.57) (137.25) 2.91 (33.22) (50.71) (52.38) (154.41) (155.10) (118.4) pt
ROIC (20.98) (20.01) (133.71) (210.57) 0.00 342.71 (233.42) 0.00 0.00 0.00 0.00 +21.0 pt
ROE (45.87) (52.44) (126.21) (401.38) (232.54) 3.71 (44.41) (80.50) (117.39) 1,115.49 (557.21) +1,161.4 pt
People
People Employees 763 845 703 728 152 429 483 337 312 280 — (10.5%)
Revenue/emp, $m 0.02 0.06 0.07 0.07 0.06 0.17 0.12 0.09 0.11 0.10 — +23.4%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026

XWELL, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MDXH MDxHealth SA $14.4M — (loss-making) — (loss-making) +12.01% (above 0%: growing) n/m −200.20% (below 0%: shrinking) 65.75% (18.74%) Compare
NDRA ENDRA Life Sciences Inc. $7.5M — (loss-making) — (loss-making) −98.80% (below 0%: shrinking) n/m +15.04% (above 0%: growing) 0.00% 0.00% Compare
TTOO T2 Biosystems, Inc. $6.5M — (loss-making) — (loss-making) +34.85% (above 0%: growing) n/m +53.36% (above 0%: growing) (106.60%) (511.89%) Compare
XWEL XWELL, Inc. $6.1M — (loss-making) — (loss-making) −7.08% (below 0%: shrinking) n/m −43.02% (below 0%: shrinking) 41.26% (29.45%)
BIAF bioAffinity Technologies, Inc. $3.3M — (loss-making) — (loss-making) +18.99% (above 0%: growing) n/m −23.69% (below 0%: shrinking) 27.98% (220.77%) Compare
DMTKQ DermTech, Inc. $3.3M — (loss-making) — (loss-making) +10.58% (above 0%: growing) n/m +24.87% (above 0%: growing) 18.54% (533.37%) Compare
ADVB Advanced Biomed Inc. $3.1M 0.3× — — n/m −101.33% (below 0%: shrinking) — 0.00% Compare
AWHL Aspira Women's Health Inc. $2.4M — (loss-making) — (loss-making) −14.89% (below 0%: shrinking) n/m −24.57% (below 0%: shrinking) 55.28% (89.69%) Compare
ISPC iSpecimen Inc. $2.0M — (loss-making) — (loss-making) −78.70% (below 0%: shrinking) n/m −257.73% (below 0%: shrinking) 45.23% (897.30%) Compare
Median of peers $3.3M — — +10.58% — −24.13% 27.98% (155.23%)

All 49 Diagnostics & Research stocks →

XWELL, Inc. (XWEL) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/XWEL · Data as of Oct 25, 2026 · For information only; not investment advice. · © 2026 stockrow.com